A Systematic Review Of Phosphodiesterase-5 Inhibitor In The Treatment Of Chronic Lung Disease-related PH

Objective: To systematically evaluate the effectiveness and safety of phosphodiesterase-5 inhibitors(PDE5i)in the treatment of chronic lung disease-related PH.Methods: We systematically searched Pub Med,EMBASE,Cochrane Library,CNKI,Wanfang Data and Weipu database for comprehensive literature reporting PDE5 i for randomized controlled trials(RCT)of Chronic lung disease related-PH from inception to July,2020.Data statistics were conducted by stata13.1 software.Results: A total of 7 RCTs involving 553 patients were included.Our data demonstrates that PDE5 i can improve 6MWD [MD=24.32,95%CI(7.52,41.12),P=0.005],m PAP[MD=-2.74,95% CI(-4.32,-1.25),P<0.001] and PASP[MD=-5.63,95%CI(-9.18,-2.07),P=0.002] of chronic lung disease-related PH,compared with the control group.However,Borg dyspnea index [MD=-0.11,95%CI(-1.15,0.93),P=0.836],SGRQ score[MD=-7.14,95%CI(-17.55,3.26),P=0.178] and SF-36 score[MD=2.59,95%CI(-1.65,6.83),P=0.232] have no significant difference between thos e two groups.Finally,PDE5 i increases the incidence of digestive tract adverse reactions[RR=2.28,95%CI(1.29,4.02),P=0.005].Conclusion: The available evidence shows that PDE5 i is safe and effective for the treatment of chronic pulmonary disease related-PH and can improve the patients’ 6MWD and pulmonary artery pressure.